Miller Steve 4

4 · CATALYST PHARMACEUTICALS, INC. · Filed Nov 24, 2025

Form 4

Period: 2025-11-20

VP Development & Management

Transactions

Exercise/Conversion
Common stock, par value $0.001 per share
2025-11-21+8,267→ 1,067,930 total
Award
Options to purchase common stock
2025-11-20+158,454→ 1,457,963 total
Exercise: $22.77Exp: 2032-11-20→ Common Stock (158,454 underlying)
Award
Restricted Stock Units
2025-11-20+47,826→ 1,489,255 total
→ Common Stock (47,826 underlying)
Exercise/Conversion
Restricted Stock Units
2025-11-21−8,267→ 1,497,522 total
→ Common Stock (8,267 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
[F2]Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027, and 1/3rd on November 20, 2028.
[F3]Shares of common stock will be delivered to the Reporting Person upon vesting.
[F4]Derivative securities vest in three equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
[F5]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.

Documents

1 file